If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
60
results.
Updated on
13/07/2025 [06:45:00]
Results 25 to 50 of 60
Absstract of: WO2025139121A1
Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.
Absstract of: EP4578962A1
The present invention relates to a composition for amplifying a FLT3 gene, and uses thereof, and, more particularly, to a composition comprising a primer set capable of simultaneously amplifying an ITD detection region and a TKD mutation region of the FLT3 gene, and uses thereof. The composition for gene amplification, according to the present invention, enables the simultaneous performance of: diagnosis of acute myeloid leukemia (AML) in patients having FLT3-ITD mutations; determination of targeted anticancer treatment prescription for AML patients having FLT3-ITD mutations; detection of minimal residual disease (MRD) in AML patients; prognosis prediction in AML patients; and identification of drug resistance to AML tyrosine kinase inhibitors, and thus, shortens the time to derive analysis results from samples and enables efficient testing. The present invention enables the selection of correct and rapid diagnosis and treatment methods in the treatment of patients with acute myeloid leukemia, and thus is useful for early treatment and recurrence prevention.
Absstract of: AU2023331249A1
The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolerable at a dose from 10 mg to 210 mg.
Absstract of: AU2023373683A1
Methods of treating non-Hodgkin lymphoma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.
Absstract of: WO2024102361A1
A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.
Absstract of: AU2023376971A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Absstract of: WO2025137363A1
The disclosure relates, inter alia, to methods for monitoring cellular transitions associated with or indicative of a presence or a stage of a myelodysplastic syndrome-related disease.
Absstract of: WO2025137368A1
A myelodysplastic syndrome-related detection system obtains single-nucleus or single-cell transcriptome data for genes for each of a plurality of nuclei or cells. Each nucleus or cell is obtained from a sample from a different subject in a cohort. Metadata for each respective subject is obtained that indicates whether the respective subject has myelodysplastic syndrome or is healthy. The nuclei or cells are clustered into clusters by computing distances using the transcriptome data for the genes for each unique pair of nuclei or cells in the plurality of nuclei or cells and through evaluation of these distances with a criterion function. Each cluster has a subset of nuclei or cells. The metadata identifies a cluster associated with the myelodysplastic syndrome on the basis that the cluster is enriched for nuclei or cells from subjects having the myelodysplastic syndrome.
Absstract of: AU2025204331A1
PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo 3,4-dpyrimidin- l-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Formulation A Formulation B Formulation C Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazole 3,4-dpyrimidin- 1-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. un ' u n b s t r a c t o r m u l a t i o n o r m u l a t i o n Mean Ibrutinib Plasma Concentration (ng/mL) o r m u l a t i o n o r m u l a t i o n o m i n a l i m e o s t - o s e ( h ) e s c r i b e d h e r e i n a r e p h a r m a c e u t i c a l f o r m u l a t i o n s o f r u t o n ' s t y r o s i n e k i n a s e (
Absstract of: TW202440945A
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
Absstract of: US2025207202A1
The present disclosure provides kits and/or methods of detecting and identifying epigenetic patterns associated with acute myeloid leukemia and other cancers. The present disclosure also relates to treating, preventing, ameliorating, or reducing acute myeloid leukemia and other cancers.
Absstract of: WO2025134050A1
Embodiments of the present disclosure relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering a therapeutically effective amount of a BCMA x GPRC5D x CD3 trispecific antibody or trispecific binding fragment thereof, to the subject to the subject to treat the multiple myeloma.
Absstract of: WO2025137567A1
Some embodiments of the disclosure include compounds of Formula (I) and Formula (la), and compositions thereof, e.g., pharmaceutical compositions, which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the compounds (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: US2025205309A1
The disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a combination of a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion, such as XmAb24306, and a FcRH5xCD3 bispecific antibody, such as cevostamab.
Absstract of: KR20250095509A
본 발명은 miRNA500 억제제를 포함하는 T세포 림프종의 예방 또는 치료용 약제학적 조성물에 관한 것으로, 본 발명의 miRNA500 억제제를 포함하는 T세포 림프종의 예방 또는 치료용 약제학적 조성물은 miRNA500의 발현, 기능 또는 활성을 억제 또는 하향 조절하여 T세포 림프종에 대한 항종양 활성을 나타내므로, T세포 림프종의 예방 또는 치료 용도로 유용하게 이용될 수 있다.
Absstract of: WO2025132479A1
The role of pro- and anti-inflammatory macrophages in disease depends on the specific disease and the balance between the two types of macrophages. Imbalances can lead to the development or progression of diseases, and targeting macrophage function may be a potential therapeutic approach for certain diseases. For example, by altering the phenotype and function of TAM-M2, it is possible to shift the immune response from an anti-inflammatory to a pro-inflammatory state, which may help reduce tumor progression. Here, the inventors demonstrate the ability of Gilteritinib to reprogram primary human macrophages. Gilteritinib is a targeted therapy used in the treatment of acute myeloid leukemia (AML) with a specific genetic mutation called FLT3-internal tandem duplication (FLT3-ITD) or a tyrosine kinase domain (TKD) mutation. Accordingly, the present invention relates to an FLT3 inhibitor to modulate the immune environment and enhance existing therapies by blocking immunosuppressive immune cells.
Absstract of: US2025205248A1
A method of a clinical use of varenicline apart from a smoking cessation is provided, including supressing inflammatory cytokines with the varenicline and repositioning the varenicline as an anti-inflammatory drug. The varenicline is repositioned in an LPS-induced in-vitro inflammation model by using a commercially available and widely used immortalized macrophage cell line obtained from male adult Balb/c mice and transformed by Abelson murine leukemia virus.
Absstract of: US2025206835A1
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
Absstract of: AU2023406508A1
The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsive to AML treatment regimes, the methods comprising identifying the presence or absence of monocytic leukemia stem cells (m-LSCs), including CD70+ m-LSCs, in a sample from a subject.
Absstract of: US2025195678A1
The present application relates to a conjugate comprising an amatoxin, a target-binding moiety wherein the target is CD20, i.e., a CD20-binding moiety, and optionally a linker linking said amatoxin and said CD20-binding moiety. The invention further relates to the synthesis of said conjugate. In addition, the invention relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of B-cell and/or lymphoma associated diseases and/or malignancies.
Absstract of: AU2023405289A1
The present invention relates to a CD229 and a BCMA targeting moiety, wherein the CD229 targeting moiety is an antibody, F(ab')2, Fab, scFab or scFv. The present invention further provides CARs, nucleic acid, cells, pharmaceutical compositions and kits comprising the CD229 and BCMA targeting moiety. Methods of treatment of a CD229-positive cancer, preferably Multiple Myeloma, are also provided.
Absstract of: US2025197392A1
The present invention relates to crystalline forms of an inhibitor of menin/mixed lineage leukemia (MLL) protein-protein interaction. The present invention also relates to pharmaceutical compositions comprising crystalline forms of an inhibitor of menin/mixed lineage leukemia (MLL) protein-protein interaction. These crystalline forms and pharmaceutical compositions comprising said crystalline forms may be useful for treating diseases such as cancer.
Absstract of: US2025195646A1
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Absstract of: US2025195653A1
The present disclosure relates to methods for treating or preventing a leukemia or a myelodysplastic syndrome in a subject in need thereof, said method comprising administering to the subject an effective amount of a combination comprising: (i) a binding protein comprising a first antigen binding domain (ABD) with binding specificity to CD123 and a second (ABD) with binding specificity to NKp46; and one or both of: (ii) a BCL-2 inhibitor, and (iii) a DNA hypomethylating agent.
Nº publicación: US2025197510A1 19/06/2025
Applicant:
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS [DE]
EBERHARD KARLS UNIV TUEBINGEN [DE]
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES \u00D6FFENTLICHEN RECHTS,
EBERHARD KARLS UNIVERSIT\u00C4T T\u00DCBINGEN
Absstract of: US2025197510A1
The present invention provides novel human fms related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and/or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3xCD3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.
BOPI
Electronic site
